Form 8-K - Current report:
SEC Accession No. 0001213900-22-059746
Filing Date
2022-09-28
Accepted
2022-09-28 16:05:14
Documents
14
Period of Report
2022-09-28
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea166406-8k_citiuspharm.htm   iXBRL 8-K 27495
2 PRESS RELEASE DATED SEPTEMBER 28, 2022. ea166406ex99-1_citiuspharm.htm EX-99.1 15702
3 GRAPHIC image_001.jpg GRAPHIC 4477
  Complete submission text file 0001213900-22-059746.txt   228406

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ctxr-20220928.xsd EX-101.SCH 3275
5 XBRL LABEL FILE ctxr-20220928_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE ctxr-20220928_pre.xml EX-101.PRE 22391
8 EXTRACTED XBRL INSTANCE DOCUMENT ea166406-8k_citiuspharm_htm.xml XML 3598
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38174 | Film No.: 221276052
SIC: 2834 Pharmaceutical Preparations